| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Karen Zagorski, Gor Chailyan, Armine Hovakimyan, Tatevik Antonyan, Sepideh Kiani Shabestari, Irina Petrushina, Hayk Davtyan, David H Cribbs, Mathew Blurton-Jones, Eliezer Masliah, Michael G Agadjanyan, Anahit Ghochikya. Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein. International journal of molecular sciences. vol 23. issue 11. 2022-06-10. PMID:35682759. |
parkinson's disease (pd) and dementia with lewy bodies (dlb) are characterized by the aberrant accumulation of intracytoplasmic misfolded and aggregated α-synuclein (α-syn), resulting in neurodegeneration associated with inflammation. |
2022-06-10 |
2023-08-14 |
mouse |
| Tim E Moors, Daniel Mona, Stefan Luehe, Gonzalo Duran-Pacheco, Liz Spycher, Olaf Mundigl, Klaus Kaluza, Sylwia Huber, Melanie N Hug, Thomas Kremer, Mirko Ritter, Sebastian Dziadek, Gregor Dernick, Wilma D J van de Berg, Markus Britschg. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta neuropathologica communications. vol 10. issue 1. 2022-06-06. PMID:35659116. |
based on immunostainings and biochemical analyses, certain post-translationally modified alpha-synuclein (asyn) variants, including c-terminally truncated (ctt) and serine-129 phosphorylated (pser129) asyn, are proposed to be involved in the pathogenesis of synucleinopathies such as parkinson's disease with (pdd) and without dementia (pd), dementia with lewy bodies (dlb), and multiple system atrophy (msa). |
2022-06-06 |
2023-08-14 |
human |
| Fernando L Pagan, Yasar Torres-Yaghi, Michaeline L Hebron, Barbara Wilmarth, R Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Mouss. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimer's & dementia (New York, N. Y.). vol 8. issue 1. 2022-06-06. PMID:35662832. |
bosutinib, a dual abelson/src inhibitor, was investigated in individuals with dementia with lewy bodies (dlb). |
2022-06-06 |
2023-08-14 |
Not clear |
| Ying-Tsung Chen, Satoshi Orimo, Cheng-Yu Wei, Guang-Uei Hung, Shieh-Yueh Yang, Pai-Yi Chi. Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease. Frontiers in aging neuroscience. vol 14. 2022-06-06. PMID:35663565. |
an abnormal increase of α-synuclein in the brain is the hallmark of dementia with lewy bodies (dlb). |
2022-06-06 |
2023-08-14 |
Not clear |
| Lara Blömeke, Marlene Pils, Victoria Kraemer-Schulien, Alexandra Dybala, Anja Schaffrath, Andreas Kulawik, Fabian Rehn, Anneliese Cousin, Volker Nischwitz, Johannes Willbold, Rebecca Zack, Thomas F Tropea, Tuyen Bujnicki, Gültekin Tamgüney, Daniel Weintraub, David Irwin, Murray Grossman, David A Wolk, John Q Trojanowski, Oliver Bannach, Alice Chen-Plotkin, Dieter Willbol. Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting. NPJ Parkinson's disease. vol 8. issue 1. 2022-06-02. PMID:35655068. |
in this work, we measured asyn and tau aggregate concentrations of 237 cerebrospinal fluid (csf) samples from five cohorts: parkinson's disease (pd), dementia with lewy bodies (dlb), alzheimer's disease (ad), progressive supranuclear palsy (psp), and a neurologically-normal control group. |
2022-06-02 |
2023-08-14 |
human |
| Anna Emdina, Peter Hermann, Daniela Varges, Sabine Nuhn, Stefan Goebel, Timothy Bunck, Fabian Maass, Matthias Schmitz, Franc Llorens, Niels Kruse, Paul Lingor, Brit Mollenhauer, Inga Zer. Baseline Cerebrospinal Fluid α-Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline. Diagnostics (Basel, Switzerland). vol 12. issue 5. 2022-05-28. PMID:35626415. |
no fluid biomarker for parkinson's disease (pd) has been established to date, but α-synuclein, a major component of lewy bodies in pd and dementia with lewy bodies (dlb), has become a promising candidate. |
2022-05-28 |
2023-08-13 |
Not clear |
| Ana Lopez, Alena Gorb, Nuno Palha, Angeleen Fleming, David C Rubinsztei. A New Zebrafish Model to Measure Neuronal α-Synuclein Clearance In Vivo. Genes. vol 13. issue 5. 2022-05-28. PMID:35627253. |
the accumulation and aggregation of α-synuclein (α-syn) is a common characteristic of synucleinopathies, such as parkinson's disease (pd), dementia with lewy bodies (dlb) or multiple system atrophy (msa). |
2022-05-28 |
2023-08-13 |
zebrafish |
| Aikaterini Foska, Ioanna Tsantzali, Eleni Sideri, Maria Ioanna Stefanou, Eleni Bakola, Dimitrios K Kitsos, Christina Zompola, Anastasios Bonakis, Sotirios Giannopoulos, Konstantinos I Voumvourakis, Georgios Tsivgoulis, George P Paraskeva. Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies. Medicina (Kaunas, Lithuania). vol 58. issue 5. 2022-05-28. PMID:35630029. |
the use and interpretation of diagnostic cerebrospinal fluid (csf) biomarkers for neurodegenerative disorders, such as dementia with lewy bodies (dlb), represent a clinical challenge. |
2022-05-28 |
2023-08-13 |
Not clear |
| Regina Kurapova, Leonidas Chouliaras, John T O'Brie. The promise of amplification assays for accurate early detection of α-synucleinopathies: A review. Experimental gerontology. 2022-05-27. PMID:35623540. |
lewy body dementia encompasses the common neurodegenerative disorders dementia with lewy bodies (dlb) and parkinson's disease dementia (pdd). |
2022-05-27 |
2023-08-13 |
human |
| Sindhu Menon, Sabrina Armstrong, Amir Hamzeh, Naomi P Visanji, Sergio Pablo Sardi, Anurag Tando. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Frontiers in neurology. vol 13. 2022-05-26. PMID:35614915. |
α-synuclein (asyn) is a key pathogenetic factor in a group of neurodegenerative diseases generically known as synucleinopathies, including parkinson's disease (pd), dementia with lewy bodies (dlb) and multiple system atrophy (msa). |
2022-05-26 |
2023-08-13 |
Not clear |
| Steve MacDonald, Ayushi Samir Shah, Babak Tous. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update. Drugs & aging. 2022-05-26. PMID:35619045. |
the term lewy body dementia refers to either of two related diagnoses: dementia with lewy bodies (dlb) and parkinson's disease dementia (pdd). |
2022-05-26 |
2023-08-13 |
Not clear |
| Gemma Roberts, Joseph Pm Kane, Jim Lloyd, Michael Firbank, Paul Christopher Donaghy, George S Petrides, John-Paul Taylor, John O'Brien, Alan J Thoma. Can early phase cardiac [123I]mIBG images be used to diagnose Lewy body disease? Nuclear medicine communications. 2022-05-23. PMID:35603421. |
some studies have suggested that cardiac [123i]metaiodobenzylguanidine images obtained 15-20 min after tracer administration are as accurate for dementia with lewy bodies (dlb) diagnosis as standard images acquired after a delay of 3-4 h; some suggest delayed imaging is preferable. |
2022-05-23 |
2023-08-13 |
Not clear |
| Jingwei Sim, Huihua Li, Shahul Hameed, Simon Kang Seng Tin. Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease. JAMA neurology. 2022-05-23. PMID:35604656. |
the early-onset form of dementia with lewy bodies (dlb) is poorly understood. |
2022-05-23 |
2023-08-13 |
Not clear |
| Rose B Creed, Adeel A Memon, Sindhu P Komaragiri, Sandeep K Barodia, Matthew S Goldber. Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function. Acta neuropathologica communications. vol 10. issue 1. 2022-05-23. PMID:35606853. |
antibodies specific for α-synuclein phosphorylated at serine 129 (ps129) are selective for the pathological protein aggregates that are characteristic of parkinson's disease (pd) and other synucleinopathies, such as dementia with lewy bodies (dlb) and multiple system atrophy (msa). |
2022-05-23 |
2023-08-13 |
mouse |
| Masaki Iked. [Treatment and Care for Elderly Patients with Dementia with Lewy Bodies Presenting with Delusional Misidentification Syndrome Including Capgras Syndrome: How to Respond and Intervene from a Neurologist's Perspective]. Brain and nerve = Shinkei kenkyu no shinpo. vol 74. issue 5. 2022-05-19. PMID:35589665. |
aged patients with dementia with lewy body (dlb) present with delusional misidentification syndrome and occasionally capgras' syndrome. |
2022-05-19 |
2023-08-13 |
Not clear |
| Arina Yazawa, Kenneth Hensley, Toshio Ohshim. Effects of Lanthionine Ketimine-5-Ethyl Ester on the α-Synucleinopathy Mouse Model. Neurochemical research. 2022-05-19. PMID:35589915. |
potentially druggable mechanisms underlying synaptic deficits seen in parkinson's disease (pd) and dementia with lewy bodies (dlb) are under intense interrogations. |
2022-05-19 |
2023-08-13 |
mouse |
| Christopher Simon, Tomoko Soga, Nafees Ahemad, Saatheeyavaane Bhuvanendran, Ishwar Parha. Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from α-Synuclein-Induced Toxicity In Vitro. International journal of molecular sciences. vol 23. issue 9. 2022-05-14. PMID:35563582. |
the neuropathological substrate of dementia with lewy bodies (dlb) is defined by the inextricable cross-seeding accretion of amyloid-β (aβ) and α-synuclein (α-syn)-laden deposits in cholinergic neurons. |
2022-05-14 |
2023-08-13 |
human |
| Vincenzo Donadio, Alex Incensi, Giovanni Rizzo, Gunilla T Westermark, Grazia Devigili, Rosa De Micco, Alessandro Tessitore, Dag Nyholm, Sara Parisini, Dag Nyman, Gioacchino Tedeschi, Roberto Eleopra, Martin Ingelsson, Rocco Liguor. Phosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. Brain : a journal of neurology. 2022-05-13. PMID:35552610. |
this cross-sectional diagnostic study evaluated skin p-syn in 96 patients: 46 with probable msa (29 msa-p and 17 msa-c), 34 with parkinson's disease (pd) and 16 with dementia with lewy bodies (dlb). |
2022-05-13 |
2023-08-13 |
human |
| Sreelakshmi Menon, Farzana Zerin, Ajay K Pandey, Raquibul Hasa. VX-745 Inhibits Smooth Muscle Cell p38 Mitogen-Activated Protein Kinase Alpha (MAPKα) and Heat-Shock Protein 27 (Hsp27) Phosphorylation to Induce Vasodilation in Resistance Mesenteric Arteries. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 36 Suppl 1. 2022-05-13. PMID:35553036. |
vx-745, a selective inhibitor of the alpha isoform of the mitogen-activated serine/threonine protein kinase p38 mapk, is under clinical investigation for its efficacy in alzheimer's disease (ad) and dementia with lewy bodies (dlb). |
2022-05-13 |
2023-08-13 |
rat |
| Saira Saeed Mirza, Usman Saeed, Joel Ramirez, Nathan Herrmann, Donald T Stuss, Sandra E Black, Mario Maselli. Effects of white matter hyperintensities, neuropsychiatric symptoms, and cognition on activities of daily living: Differences between Alzheimer's disease and dementia with Lewy bodies. Alzheimer's & dementia (Amsterdam, Netherlands). vol 14. issue 1. 2022-05-05. PMID:35510093. |
disability is common across alzheimer's disease (ad) and dementia with lewy bodies (dlb). |
2022-05-05 |
2023-08-13 |
Not clear |